<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03627013</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N-KLP-TX-III/07-AT/17</org_study_id>
    <secondary_id>2017-002198-20</secondary_id>
    <nct_id>NCT03627013</nct_id>
  </id_info>
  <brief_title>Custodiol-N Solution Compared With Custodiol Solution in Organ Transplantation (Kidney, Liver and Pancreas)</brief_title>
  <official_title>A Prospective, Randomized, Single Blind, Multicentre Phase III Study on Organ Preservation With Custodiol-N Solution Compared With Custodiol Solution in Or-gan Transplantation (Kidney, Liver and Pancreas)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. F. Köhler Chemie GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. F. Köhler Chemie GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Synopsis Title of Study A prospective, randomized, single blind multicentre phase III study&#xD;
      on organ preservation with Custodiol-N compared with Custodiol solution in organ&#xD;
      transplantation (kidney, liver and pancreas)&#xD;
&#xD;
      Protocol number: CL-N-KLP-TX-III/07-AT/17&#xD;
&#xD;
      Trial design The study design is a prospective, randomized, single blind, multicentre, phase&#xD;
      III comparison study of organ perfusion intended to demonstrate non-inferiority of&#xD;
      Custodiol-N against Custodiol in organ transplantation of kidney, combined kidney-pancreas&#xD;
      and liver.&#xD;
&#xD;
      Intended duration of study The overall duration for the trial is expected to be approximately&#xD;
      30 months. The du-ration of the trial for each subject is expected to be 3 months&#xD;
      (transplantation and a follow-up period of 90 days).&#xD;
&#xD;
      Purpose of the study&#xD;
&#xD;
      The objective of this investigation is to demonstrate non-inferiority of graft preservation&#xD;
      with Custodiol-N compared to Custodiol with respect to both graft function and injury after&#xD;
      transplantation of kidney, liver or combined kidney-pancreas.&#xD;
&#xD;
      Patient selection The study population will be selected from patients who will undergo&#xD;
      kidney, liver or combined kidney-pancreas transplantation. Patients of each gender will be&#xD;
      included in the study.&#xD;
&#xD;
      Planned number of patients (recipients)&#xD;
&#xD;
      In total N=614 including:&#xD;
&#xD;
      Kidney 412 (including approx. 30 combined kidney-pancreas)&#xD;
&#xD;
      Liver 202&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kidney: - delayed graft function: Dialysis requirement during the first week af-ter transplantation</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver: - area under the curve (AUC) GPT (ALT) after transplantation during 7 days (minimum 1 measurement per day)</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">614</enrollment>
  <condition>Kidney Failure</condition>
  <condition>Liver Failure, Chronic</condition>
  <condition>Kidney-Pancreas Failure</condition>
  <arm_group>
    <arm_group_label>Kidney Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney/Pancreas Custodiol-N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Kidney/Pancreas Custodiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol-N Solution</intervention_name>
    <description>Perfusion</description>
    <arm_group_label>Kidney Custodiol-N</arm_group_label>
    <arm_group_label>Kidney/Pancreas Custodiol-N</arm_group_label>
    <arm_group_label>Liver Custodiol-N</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custodiol HTK Solution</intervention_name>
    <description>Perfusion</description>
    <arm_group_label>Kidney Custodiol</arm_group_label>
    <arm_group_label>Kidney/Pancreas Custodiol</arm_group_label>
    <arm_group_label>Liver Custodiol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All organs (kidney, combined kidney - pancreas and liver) Donor criteria&#xD;
&#xD;
          -  deceased adult (≥18 years) donors fulfilling the criteria for organ donation Patient&#xD;
             (recipient) criteria&#xD;
&#xD;
          -  recipients awaiting their transplant&#xD;
&#xD;
          -  recipients ≥18 years&#xD;
&#xD;
          -  recipients' signed informed consent before the transplantation Kidney / combined&#xD;
             kidney - pancreas recipients&#xD;
&#xD;
          -  n/a Liver recipient&#xD;
&#xD;
          -  full organ transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All organs (kidney, combined kidney - pancreas and liver) Donor criteria&#xD;
&#xD;
          -  donors whose organs are all allocated out of Austria&#xD;
&#xD;
          -  general refusal of organ donation&#xD;
&#xD;
          -  donation after cardiac death (DCD) Patient (recipient) criteria&#xD;
&#xD;
          -  pregnant or lactating patients&#xD;
&#xD;
          -  recipients participating in any interventional study (e.g. another study involving&#xD;
             compound/interventions aimed at the reduction of preservation and / or ischemia /&#xD;
             reperfusion injury)&#xD;
&#xD;
          -  all combined allocations other than pancreas and kidney&#xD;
&#xD;
        Kidney / combined kidney -pancreas recipient&#xD;
&#xD;
          -  double kidney transplantation&#xD;
&#xD;
          -  pancreas retransplantation&#xD;
&#xD;
          -  machine perfusion According to the KDIGO-Guidelines (2009) all patients with PRA &gt;0%&#xD;
             are excluded&#xD;
&#xD;
        Liver recipient&#xD;
&#xD;
          -  retransplantation&#xD;
&#xD;
          -  machine perfusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Astrid Friedel</last_name>
    <phone>+4332638578017</phone>
    <email>astrid.friedel@medunigraz.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schemmer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 8, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2018</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>End Stage Liver Disease</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

